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and Department of Medical Sciences, University of Trieste, 34149 Trieste, ItalySummary IntroductionThe importance of a correct balance between oxidative and
reductive events has been shown to have a paramount effect on
cell function for quite a long time. However, in spite of this body
of rapidly growing evidence, the implication of the alteration of
the redox state in human disease has been so far much less
appreciated. Liver diseases make no exception. Although not fully
comprehensive, this article reports what discussed during an
EASL Basic School held in 2012 in Trieste, Italy, where the effect
of the alteration of the redox state was addressed in different
experimental and human models. This translational approach
resulted in further stressing the concept that this topic should
be expanded in the future not only to better understand how oxi-
dative stress may be linked to a liver damage but also, perhaps
more important, how this may be the target for better, more
focused treatments. In parallel, understanding how alteration of
the redox balance may be associated with liver damage may help
deﬁne sensitive and ideally early biomarkers of the disorder.
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etry; LC, liquid chromatography.All living organisms have to cope with harmful by-products of
oxygen such as O2, H2O2, and OH (collectively called free
radical or reactive oxygen species, here referred to as ROS), which
appeared on Earth approximately 2 billion years ago and
provoked the development of cell defense mechanisms [1].
However, the history of free radicals is much younger since their
formation in cells was ﬁrst documented about 60 years ago by a
study demonstrating that harmful oxygen species may be pro-
duced in animals and plants as mediators of the damaging effects
of radiation [2]. It was only after the discovery of the existence of
superoxide dismutase enzyme (erythrocuprein or SOD), which
catalyzes O2 dismutation to H2O2 [3], that the biological
interest in ROS became apparent. It soon became clear that living
organisms are capable of inducing their antioxidant defense
systems by relatively rapid mechanisms to cope with the
oxidative stress due to an imbalance between the generation of
ROS and the antioxidant defense capacity of the cell. Both
animals and certain plants can induce SOD upon increased
exposure to oxygen, paraquat (a known producer of O2), and
X irradiation [4]. Within the body, tissues with a higher oxygen
consumption rate, such as liver, heart, and brain, constitutively
express greater antioxidant enzymes than those with lower
oxygen consumption [5].
Oxidative stress is a major pathogenetic event occurring in
several liver diseases, ranging from metabolic to proliferative
disorders. Main sources of ROS are represented by mitochondria
and cytochrome P450 enzymes in the hepatocyte, Kupffer cells,
and neutrophils [6,7]. Oxidative stress affects major cellular
components including lipids, DNA, and proteins [8]. Through
modulation of protein structure/function, ROS can inﬂuence gene
expression proﬁle by affecting intracellular signal transduction
pathways [9]. While several enzymatic and non-enzymatic
markers of chronic oxidative stress are well known in the liver,
early protein targets of oxidative injury are yet poorly deﬁned
[10]. Identiﬁcation of these biomarkers will enable early detec-
tion of liver diseases and allow monitoring the degree of liver
damage, the response to pharmacological therapies and the
development of new therapeutic approaches. In the era of
molecular medicine, new proteomic methodologies promise to
establish a relationship between pathological hallmarks of the
disease and protein structural/functional modiﬁcations, allowing
a better understanding and a more rational therapy of several
liver disorders.13 vol. 58 j 365–374
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Fig. 1. Etiologic factors and central role of oxidative stress in the pathogenetic development of hepatic diseases. Oxidative stress is the major pathogenic event
occurring in several liver disorders. Chronic liver injury due to HBV and HCV infection, inadequate alcohol consumption and metabolic disorders determine a pro-oxidative
state causing protein and DNA damage and lipid peroxidation. Instauration of hepatocyte oxidative stress condition results in liver ﬁbrosis and cirrhosis, which may lead to
hepatocellular carcinoma.
ReviewLiver diseases are frequent pathologies worldwide [11] and
may be divided into acute and chronic on the basis of the persis-
tence of liver injury. Acute liver injuries (ALI) are characterized
by a rapid resolution and a complete restitution of normal organ
architecture/function after the elimination of the cause, while
chronic liver diseases (CLD) are characterized by persistent liver
damage with progressive alteration of organ function caused by
increased cellular damage [12]. The most common causes at the
basis of CLD are viral infections sustained by hepatitis C and B
viruses (HCV and HBV), alcohol abuse and alterations of lipid/
carbohydrate metabolism, also known as non-alcoholic fatty liver
disease (NAFLD). All these clinical features are major risk factors
for HCC development [13]. However, regardless of the different
etiology and natural course, a common landmark of all types of
liver injury is an increased production of ROS (Fig. 1) [10].Oxidative stress and liver damage
ROS and reactive nitrogen species (RNS), such as NO, NO+, NO,
and ONOO, are critical intermediates in the normal physiology366 Journal of Hepatology 201and pathophysiology of the hepatocyte. When the equilibrium
between ROS generation and the antioxidant defense of the cell
is disrupted, a ‘‘net’’ oxidative stress results. In the liver, free rad-
icals triggered by ROS and RNS are created by neutrophils, Kupf-
fer cells, mitochondria, and cytochromes P450 (for more details
about ROS and NOS generation see [14]). The damage created
by oxidative stress affects all major cellular components, includ-
ing lipids, proteins and DNA [15]. The relevance of cellular redox
imbalance in liver pathologies is outlined by a number of studies
in patients with viral, alcoholic or non-alcoholic fatty liver dis-
eases [16–19], pointing to a correlation between organ damage
and increase in pro-oxidant cellular markers, such as malondial-
dehyde (MDA), 4-hydroxynonenal (4-HNE) and their protein
adducts, associated with a concomitant decrease of antioxidants
[16,19,20]. These markers may contribute to monitor the extent
of liver damage; although their alteration may represent an epi-
phenomenon due to the particular cellular stress [10]. Chemical
modiﬁcation of essential biomolecules by ROS may cause their
functional inactivation and lead to either cell death or an adap-
tive cellular response. In particular, a complex functional modu-
lation of the cellular protein repertoire occurs upon oxidative3 vol. 58 j 365–374
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ig. 2. Main pathways for the formation of ROS and NOS.Mitochondria are the
ajor source of cellular ROS during respiratory processes. Electron ﬂow leads to
e formation of superoxide anion (O2) that is generated by the univalent
duction of molecular oxygen (O2). This process may also be mediated by
nzymes such as NADPH oxidase and xanthine oxidase. Superoxide dismutase
OD) catalyzes the dismutation of two superoxide anions into hydrogen peroxide
2O2) and oxygen. H2O2 can react with reduced transition metals, via Fenton’s
action, to produce the highly reactive hydroxyl radical (OH). Alternatively,
2O2 could be converted into water by enzymes catalase (CAT) and glutathione
eroxidase (GPX). Due to its relative long half-life (105 s), H2O2 could damage
pids, DNA and proteins leading to cell death. Inﬂammatory cells are the main
urce of TNFa. This cytokine contribute to mitochondrial dysfunction indirectly
ading to the formation of RNS as a consequence of the induction of nitric oxide
nthase 2 (NOS2) and formation of nitric oxide (NO), which reacting with O2
enerates peroxynitrate (ONOO).
JOURNAL OF HEPATOLOGY
insult [21,22] through the ROS-dependent modiﬁcation of spe-
ciﬁc amino acids, such as Cys, Trp, Tyr, His, Arg, and Lys [23].
ROS also behave as molecular second messengers within the
cell, as they can be generated during triggering of particular cel-
lular responses by cytokines, hormones, growth factors, and other
soluble mediators, such as extracellular ATP [24]. Through the
activation of protein kinases and phosphatases, intracellular
ROS may directly or indirectly control the function of transcrip-
tion factors, such as Nrf1 and NF-jB, thus leading to profound
changes in cellular gene expression proﬁle [25,26]. Moreover,
ROS perpetuate and potentiate their own effects by inﬂuencing
transcription and activation of cytokines and growth factors,
responsible for further ROS production leading to the onset of
the so called ‘vicious cycle’ [20]. Depending on the cell type
and intensity/duration of the oxidative stress affecting cells,
ROS may therefore act either as pro-apoptotic molecules or stim-
ulators of cell proliferation.
Cellular defenses coping with ROS generation are multiple and
include enzymatic (superoxide anion dismutase, catalase, GSH
peroxidases, peroriredoxins, glutaredoxins, thuoredoxins, sulﬁre-
doxins) and non-enzymatic antioxidants (vitamins A, C, and E,
GSH, urate, bilirubin) (for more details about antioxidant mecha-
nisms see [6]). The coordinated action of antioxidant enzymes
ensures efﬁcient ROS removal. Therefore, oxidative stress may
be deﬁned as an imbalance between the generation of ROS and
the antioxidant defense capacity of the cell. In spite of the fact
that the innovative concept that oxidative stress requires a ﬁne
balance within antioxidant systems is gaining relevance, large-
scale interventional studies in humans with antioxidants have
been inconsistent in demonstrating medical beneﬁts, particularly
in cancer patients [27,28]. The idea that redox signaling may spe-
ciﬁcally involve discrete pathways within cells suggests the pos-
sibility that oxidative stress can actually occur without an overall
imbalance of pro-oxidants and antioxidants, and that the disrup-
tion of redox-sensitive signaling pathways can lead to metabolic
and organ speciﬁcity in oxidative stress [6].
Some enzymes have a fundamental importance in maintain-
ing cell functions during oxidative stress conditions. The nuclear
protein Apurinic Apyrimidinic Endonuclease/Redox Effector Fac-
tor 1 (APE1/Ref-1) is a paradigmatic example [29]. This protein
is involved in both transcriptional regulation of gene expression
during adaptive cellular response to oxidative stress and the base
excision repair pathway of DNA lesions generated as a conse-
quence of ROS-induced base damages [29]. A signiﬁcant upregu-
lation and relocalization of this protein has been described during
HCC progression, accounting for a causative role of oxidative
stress in the pathogenesis of HCC and suggesting APE1/Ref-1 as
a new biomarker of the transformation process [30].
In most of the liver diseases, of both metabolic and viral origin
and associated with transformation processes, a chronic oxida-
tive stress condition represents the main common determinant.
During acute and chronic damage, hepatocytes are exposed to
increased levels of oxidants, cytokines and bile acids. In spite of
their powerful antioxidant resources, hepatocytes suffer from
the cytotoxic effect of oxidative stress, leading to cell death. It
is still a matter of debate whether cell death induced by ROS
occurs either by necrosis or apoptosis, and which are the path-
ways involved in dead processes [31,32].
In the liver, inﬂammatory cells, cholangiocytes, and Kupffer
cells are the main sources of tumor necrosis factor a (TNFa).
TNFa, together with other inﬂammatory cytokines, contributeJournal of Hepatology 201F
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gto mitochondrial dysfunction by interfering with the mitochon-
drial respiratory chain and by forming O2 [33]. An indirect
effect of TNFa in promoting mitochondrial dysfunction is the
increased production of RNS as a consequence of the induction
of nitric oxide synthase 2 (NOS2) [34]. RNS, such as NO, NO+,
NO, and ONOO, play an important role in controlling the
cellular redox state (Fig. 2) [35]. Interestingly, some of the
physiological effects of RNS are mediated through the formation
of S-nitroso-Cys or S-nitroso-GSH intermediates [36]. RNS may
functionally inactivate proteins of the mitochondrial respiratory
chain through nitration of their Tyr residues or intermediate
formation of S-nitrosated protein adducts at Cys residues [36].
Mitochondria play a crucial role in controlling apoptotic cell
death, particularly in the hepatocyte. Activation of death recep-
tors induces ampliﬁed apoptotic pathways involving caspase 8
and mitochondrial membrane proteins, which abolish the ﬂow
of electrons in the electron transport chain (ETC), increase mito-
chondrial ROS production and ﬁnally trigger the apoptosome
(Fig. 2) [37]. ROS can also damage the mitochondria directly, by
oxidizing various mitochondrial biomolecules, or by further
increasing lipid peroxidation. Mitochondria are involved in both
fatty acids (FA) b-oxidation and ROS generation and increasing3 vol. 58 j 365–374 367
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evidence indicates that respiratory-chain defects are a key deter-
minant of mitochondrial dysfunction, which in turn occurs as a
result of ischemia/reperfusion (I/R) and excess of FA (lipotoxicity)
[38]. Mitochondrial impairment causes enhanced ROS produc-
tion, which initiates a self-sustaining loop through the generation
of MDA and 4-HNE, resulting from cellular lipid peroxidation,
which are able to inhibit cytochrome c oxidase of mitochondrial
complex IV. On the other hand, ROS per se damage both mtDNA
and Fe–S cluster enzymes of the respiratory chain, leading to
chronic organelle damage [39].
The increased availability of FA in hepatic pathologies charac-
terized by fat accumulation (NASH or ASH) determines the acti-
vation of microsomal cytochrome P-450 isoforms CYP2E1 and
CYP4A10/4A14, involved in FA --oxidation, leading to an
increased ROS production and uncoupling mitochondrial respira-
tion [38,40]. Of notice is the ﬁnding that a non-mitochondrial
source of ROS, such as the NADPH-oxidase system of Kupffer
cells, is also activated in NASH models, probably as a conse-
quence of lipoperoxide or endotoxin phagocytosis [41]. This path-
way is also present in activated hepatic stellate cells, possibly
contributing to the general oxidative stress condition. Moreover,
some viral proteins, such as the HCV protein NS5A, may affect
intracellular Ca2+ concentration and signaling, thus triggering
the elevation of ROS concentration in mitochondria and the
translocation of NF-jB and STAT-3 into the nucleus with the con-
sequent activation of target genes [42–44].
Besides the involvement in development of CLD, oxidative
stress is also generated under physiological conditions, such as
during I/R upon liver transplantation. The I/R damage of the
transplanted liver is one of the main determinants of primary
non-function or initial poor function of the graft, which may con-
tribute to a poor transplant outcome [10]. Hepatic I/R injury can
be categorized into warm I/R and cold-storage reperfusion injury
[45]. ROS are generated very early after warm ischemia (within
the ﬁrst 4 h of reperfusion) and revascularization of ischemic tis-
sue, in which the initial cell death triggers an inﬂammatory
response with activation of tissue macrophages and recruitment
of neutrophils [46]. Primary sources of ROS during hepatic I/R are
impairment of mitochondrial ETC, activation of NADPH oxidase in
neutrophils and Kupffer cells and conversion of xanthine dehy-
drogenase into the ROS-producing form xanthine oxidase [47]
(Fig. 2). Although the latter mechanism was often considered as
a critical source of ROS during I/R injury, recent evidence tends
to limit the contribution of this pathway in ROS formation [47].Role of oxidative stress during HCV infection
A close relationship exists between HCV infection and oxidative
stress, and hepatitis C virus infection is associated with severe
alteration of the host redox status [48]. Lipid peroxidation prod-
ucts are increased in serum, peripheral blood mononuclear cells
(PBMC), and liver tissue, and 4-HNE and 8-hydroxyguanosine
(8OHdG) are also elevated [49]. In addition, there is a signiﬁcant
reduction of hepatic, plasmatic, and lymphocytic GSH levels in
patients chronically infected with HCV associated with an
increased percentage of oxidized GSH (GSSG), suggesting an
increased GSH turnover [49].
This increased oxidative stress in hepatitis C may be explained
by chronic inﬂammation, and the continued generation of ROS
and NOS may be due to an increased activity of NADPH oxidase368 Journal of Hepatology 201(Nox 2 protein) of Kupffer and polymorphonuclear cells in the
liver [50]. NS3 protein of HCV has been shown to activate Nox
2 protein of phagocytes and trigger apoptosis and dysfunction
of T cells, natural killer cells, and natural killer T cells. Nox 2 pro-
tein is located on phagosomal and plasma membranes, leading to
increased generation of ROS and other reactive species that can
exert oxidative stress to the nearby cells.
The excess iron deposits found in the liver tissue of some HCV
patients may promote the generation of free radicals in these
individuals [51]. The mRNAs of TNF-a and cytochrome P-450
(CYP2E1), both of which can increase ROS production, might also
be elevated in hepatitis C patients [52]. Furthermore, there is
some indication that HCV can directly induce oxidative stress in
the hepatocyte [53]. Gene expression in HCV core has been asso-
ciated with increased ROS, decreased intracellular and/or mito-
chondrial GSH content, and increased levels of oxidized
thioredoxin and lipid peroxidation products [54,55]. Therefore,
it may be suggested that HCV produces oxidative stress through
multiple mechanisms that include chronic inﬂammation, iron
overload, and liver injury. Some of the HCV proteins may contrib-
ute to this process.
Sensitive oxidative stress biomarkers may be important in the
diagnostic approach to HCV infection and help monitor disease
progression and the efﬁcacy of therapies. However, in spite of
the amount of information available on the pathogenic role of
oxidative stress in HCV infection and the signiﬁcant advances
made in the last few years, the translation to clinical practice is
still far [56].ROS and hypoxia in HCC
Human HCC is the ﬁfth most frequent neoplasm worldwide and
the third cause of cancer-estimated deaths. There are multiple
etiological agents that are associated with the development of
HCC, the most frequent being HBV and HCV infections and
metabolic disease as NASH [57]. Globally, up to 80% of HCC is
attributable to HBV or HCV [58]. The risk of HCC is increased
5- to 15-fold in chronic HBV carriers [59] and 11.5- to 17-fold
in HCV-infected patients [60]. Antiviral therapy is effective in
preventing HCC in only a proportion of patients [61]. Moreover,
sustained clearance of HBV or HCV may be difﬁcult to accom-
plish, particularly among cirrhotic patients.
It has been shown that oxidative DNA damage in cirrhotic
HCV-infected patients is associated with increased risk of devel-
oping HCC [62]. In patients with chronic hepatitis C, an increased
8OHdG in DNA extracted from liver tissue was reported
[49,63,64]. Although these reports suggest that oxidative stress
may be involved in the progression of liver disease, they did
not show a direct participation of oxidative stress in
hepatocarcinogenesis.
Intracellular ROS generation may also represent a critical
event linking hypoxia to angiogenesis and HCC development.
Indeed, hypoxic areas are very common in HCC and hypoxia-
related induction of ROS formation has been reported to stabilize
the hypoxia-inducible factor 1a (HIF-1 a), through inhibition of
prolyl-hydroxylases (PHD) or redox-dependent activation of
protein phosphorylation cascades, and to lead to upregulation
of HIF-1 target genes [65]. Mitochondria are the major source
of ROS generated during hypoxia [66]. Hypoxia increases mito-
chondrial ROS via the transfer of electrons from ubisemiquinone3 vol. 58 j 365–374
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to molecular oxygen at the Qo site of complex III of the mitochon-
drial ETC [67]. Release of reactive oxygen species from the inner
mitochondrial membrane to the intermembrane space leads to
the activation of transcription factors, including HIF-1 a [68]. Fur-
thermore, hypoxia-induced ROS generation has been shown to
enhance the DNA binding of NF-jB through a redox dependent
mechanism, leading to transcriptional activation of target genes
[69].
Hypoxia represents a strong selective pressure reported to
favor cancer progression through the activation of adaptive tran-
scriptional programs that promote angiogenesis, cell survival,
motility, and invasiveness of malignant cells, including the ability
to induce epithelial mesenchymal transition (EMT) and increased
invasiveness in human epithelial cancer cells [70–72]. This novel,
ROS- and hypoxia-related perspective is particularly relevant to
HCC that usually develops on the background of a chronically
damaged liver. Indeed, hypoxia, through redox signaling, has
been described to induce EMT and increased invasiveness in
human liver cancer cells [71], which is relevant for a tumor like
HCC that is more invasive than metastatic [70,72]. Moreover,
aberrant angiogenesis and vascular remodeling are critical events
for HCC growth [70,72]. The angiogenic switch is sustained by
hypoxia, cytokines and GFs as well as by mutation in suppressor
genes and oncogenes, with hypoxia being the most relevant one.The metabolic syndrome: role of oxidative stress in the
progression of NAFLD
The deﬁnition of metabolic syndrome involves a group of meta-
bolic and cardiovascular risk factors that help identify subjects
at high risk of type 2 diabetes and cardiovascular disease
(CVD). Even if the term ‘‘syndrome’’ implies a speciﬁc causative
aetiology, there is not a clear, unifying pathophysiological cause
for the metabolic syndrome. Nevertheless, abdominal adiposity,
physical inactivity, and insulin resistance appear to be at the core
of this condition [73]. The latest deﬁnition of the metabolic syn-
drome, supplied by the International Diabetes Federation, shows
as typical marks: abdominal obesity, deﬁned by increased waist
circumference (P94 cm in men and P80 cm in women), and
two or more of the following factors including elevated blood
pressure, raised fasting plasma glucose, increase serum triglycer-
ide levels and/or low HDL cholesterol [74]. An increase in triglyc-
eride levels is one of the most prevalent metabolic syndrome
components. Recent epidemiological data indicate that NAFLD
is the most frequent hepatic lesion in Western countries. This
condition is often benign, but in about 20–30% of NAFLD patients
the disease can progress to NASH and cirrhosis.
Increased levels of oxidative stress have been proposed to play
a relevant pathogenic role in NAFLD progression according to the
original ‘two-hit’ theory of Day and James [75] and to the more
recent insights coming from reliable animal models [76]. Along
these lines, several mechanisms favoring increased generation
of oxidative stress mediators in NAFLD have been proposed,
including mitochondrial, increased fatty acid oxidation in either
endoplasmic reticulum (x-oxidation), by CYP-2E1 and CYP4A iso-
forms, or in peroxisomes (b-oxidation) by acyl-CoA oxidase [77].
Moreover, ROS and other oxidative stress-mediators, such as
aldehydic end-products of lipid peroxidation are believed to sus-
tain ﬁbrotic progression of chronic liver diseases of different
aetiology towards the end point of cirrhosis, being able to elicitJournal of Hepatology 201cell injury and death as well as ﬁbrosis and inﬂammatory
response [77,78].Molecular events in NASH
The accumulation of triglycerides in hepatocytes is the hallmark
of NAFLD, a spectrum of hepatic abnormalities usually associ-
ated with altered metabolism [74]. In approximately 30% of
the cases, steatosis is associated with hepatocellular damage,
evident as ballooning, inﬂammation and ﬁbrosis. This more
aggressive form of the disease, known as NASH, may be associ-
ated with ﬁbrosis and has the ability to progress to cirrhosis
and its complications, including hepatocellular carcinoma [79].
The mechanisms leading to the appearance of NASH and its
progression to ﬁbrosis are still uncertain and focus of active
investigation. Genetic factors certainly play a role, as shown
for the polymorphisms of adiponutrin (PNPLA3), which are asso-
ciated with steatosis and predisposition to injury and ﬁbrosis
[80]. Studies in animal models have increased our understand-
ing of the molecular mechanisms that lead to the appearance
and progression of NASH. A central point in the emergence of
NASH is the toxic effects of lipids accumulating in the liver, a
process known as lipotoxicity [81]. This event is mediated by
fatty acids and some of their metabolites, whereas triglycerides
represent a relatively safe form of fat storage. Of interest was
the observation that cholesterol per se may play a role in the
progression of fatty liver to more steatohepatitis. Both nutri-
tional and genetic models of hepatic steatosis showed that
the accumulation of cholesterol in mitochondria was associated
with a selective glutathione depletion which in turn was asso-
ciated with a higher sensitivity to TNF and Fas [82]. This obser-
vation pointed to the conclusion that not only the amount but
also the type of lipids accumulated in the liver may be impor-
tant, a concept conﬁrmed in different experimental models [83].
One of the consequences of lipotoxicity is the appearance of
endoplasmic reticulum stress (ERS), which results from improp-
erly folded proteins accumulating in the ER [84]. ERS is linked
to the activation of NF-jB, c-Jun N-terminal kinase, and oxida-
tive stress pathways. More recently, autophagy has also been
implicated in the pathogenesis of insulin resistance and fat-
mediated damage [85].
Another pathway strictly linked to lipotoxicity is the genera-
tion of oxidative stress-related products, which contribute to
hepatocellular damage, inﬂammation and ﬁbrosis [86]. Inﬂam-
mation is part of the wound healing response and is regulated
by a complex network of soluble mediators, including cytokines
such as TNF-a or IL-6. In this context, chemokines such as CCL2
or CCL5 also play a relevant role [87]. The chemokine system is
not only linked to inﬂammation but also contributes to the devel-
opment of ﬁbrosis via direct actions on hepatic stellate cells. In
this respect, activation of the receptors CCR5 and CCR2 play a
major role [88].
The development of steatohepatitis and ﬁbrosis is also inﬂu-
enced by extrahepatic factors. Differences in the microbiota
have been recently suggested to participate in the pathogenesis
of NASH [89]. These actions are mediated, at least in part, by
activation of the toll-like receptors, which recognize microbial
patterns providing danger signals. Adipokines, cytokines
secreted at the level of the adipose tissue, represent another
group of signals relevant to the development of steatohepatitis3 vol. 58 j 365–374 369
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and ﬁbrosis. Leptin and adiponectin exert many opposing
actions on inﬂammation and ﬁbrosis. In addition, adiponectin
limits the development of insulin resistance. Modulation of
adipokine imbalance can explain some of the favorable effects
of weight loss [90].Iron induced liver damage
Accumulating evidence indicates that deregulation of iron
metabolism is involved in the pathogenesis of ischemic/
reperfusion injury, neurodegeneration, insulin resistance and
diabetes mellitus, atherosclerosis, and liver diseases [91]. The
most studied disease model of iron toxicity is represented by
hereditary hemochromatosis (HH), where defective regulation
of systemic iron metabolism due to defective release or activity
of the hormone hepcidin leads to hepatic and later parenchymal
systemic iron overload [92]. In HH, iron accumulation within
hepatocytes has been associated with oxidative damage to DNA
and activation of ﬁbrogenesis [93], and often results in progres-
sive liver disease. In association with obesity and metabolic syn-
drome, it represents the leading cause of hepatic iron overload in
Western countries [94], with frequent progression to advanced
ﬁbrosis and HCC [95].
Although a long-lasting hypothesis is that the damaging effect
of iron is related to its ability to catalyze the generation of ROS via
the Fenton reaction, the molecular pathways of cellular and tis-
sue dysfunction are less clear. Recent data have implicated an
upregulation of the p53 pathway, which would lead to an initial
induction of antioxidant enzymes, and later to cell senescence
and death [96]. Furthermore, fatty acids would further increase
ROS production when iron accumulation is associated with fatty
liver, and, when present, excess alcohol.
A recent study by Dixon et al. describes a non-apoptotic form
of cell death dependent on the oncogenic RAS-selective lethal
small molecule erastin. This molecule triggers a unique iron-
dependent form of non-apoptotic cell death that the authors
termed ‘‘ferroptosis’’. Ferroptosis is dependent upon intracellular
iron and is morphologically, biochemically, and genetically dis-
tinct from apoptosis, necrosis, and autophagy. Erastin, like gluta-
mate, inhibits cystine uptake by the cystine/glutamate antiporter
(system x(c)()), creating a void in the antioxidant defenses of
the cell and ultimately leading to iron-dependent, oxidative
death [97].
The role of ROS in the pathogenesis of iron-related liver
damage was supported by the demonstration that a functional
promoter polymorphism of myeloperoxidase (MPO), a major
site of ROS production in phagocytes, is associated with cirrho-
sis and HCC in HH patients [98]. Similarly, in NAFLD it was
recently demonstrated that the C47T polymorphism, resulting
in a decreased import and activity of the mitochondrial SOD2
involved in the detoxiﬁcation of ROS, was strongly associated
with the susceptibility to advanced ﬁbrotic disease even when
I148M PNPLA3 genotype was controlled [99]. The same
genetic variant predisposes to cardiomyopathy and HCC in
HH [100].
Recent observations suggest that as in NASH, ERS plays an
important role in iron-induced liver injury and that ROS are
mediators of the ERS response. ERS is an adaptive response to
cellular stress induced by the accumulation of unfolded pro-
teins, caused by unbalanced oxidative stress overcoming the370 Journal of Hepatology 201protein folding capacity of ER. An excessive and protracted
ERS results in cellular dysfunction by the alteration of glucose
and lipid metabolism and by favoring cell death. Finally, the
complex interplay between iron, ROS, and ERS response was
emphasized by the evidence that accumulation of unfolded pro-
teins in ER induces hepcidin expression via the ERS response
[101], thus linking ERS to iron homeostasis. On the other hand,
oxidative stress has also been shown to decrease hepcidin
release by altering the chromatin structure of its promoter
region during HCV infection and alcohol abuse [102,103], thus
contributing to the increased iron absorption characteristic of
these diseases.
Increased ROS production leading to unbalanced oxidative
stress plays a key role in the pathogenesis of liver disease asso-
ciated with hepatic iron accumulation, due to both genetic and
acquired factors, and excess iron which may synergize with
steatosis. The mechanisms include direct stimulation of ﬁbro-
genesis, mitochondrial damage and activation of the p53
pathway, activation of the ERS response, and DNA damage,
collectively favoring HCC occurrence. Conversely, the oxidative
stress and ERS response affect iron metabolism by inﬂuencing
hepcidin expression. Therefore, the modulation of oxidative
stress represents an attractive therapeutic target for the
prevention of clinical complications of iron overload and
steatosis.Modern proteomics will help in new biomarker discovery for
early diagnosis of oxidative stress-based liver pathologies
Antioxidant supplements for liver diseases did not provide con-
vincing evidence to support or refute antioxidants in treating
liver diseases [104]. This conclusion may be due to the lack of
biomarkers predictive of severity and progression of the disease.
Accordingly, the understanding of the sources of ROS formation
during liver injury process is critical for the interpretation of
experimental results and for designing an effective therapeutic
intervention.
The liver has been the subject of dedicated investigations
since the ﬁrst introduction of basic proteomic technologies in
the early ‘90s [105]. After the launch of the Human Liver Prote-
ome Project (HLPP) in 2002, a number of holistic studies have
been undertaken on human and mouse/rat models in an attempt
to reach a functional map of the organ, expanding the proteomic
description to its ‘‘physic-ome’’ and ‘‘path-ome’’, with the aim to
accelerate the development of liver-speciﬁc diagnostics and ther-
apeutics [106]. Thus, various dozens of investigations, based on
the use of 2D chromatography/electrophoresis combined with
different MS approaches, have been published to describe the
quantitative level of liver proteins under basal conditions [107].
These researches have been performed directly on liver tissues
or, in other cases, on hepatocyte, hepatic stellate, Chang and
Kupffer cells. Moreover, a large number of differential studies
have been undertaken to describe the quantitative proteomic
variations in hepatic cells during embryo organ development
[108,109] or senescence [110], after organ transplantation/resec-
tion [111,112], following treatment with various toxic agents
[113,114], or different liver diseases. In particular, a great effort
has been spent in the proteomic analysis of in vitro models or
liver tissue of HCV [115,116] and HBV infection [117,118],
ﬁbrosis and cirrhosis [118,119], HCC [120–123], and NAFLD3 vol. 58 j 365–374
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[124,125]. Sensitive and speciﬁc biomarkers of some liver
diseases have also been searched in the serum of patients by
2-DE/MS or SELDI-MS approaches [126–128], proposing a
number of disease-associated biomarkers. Developments in
immunoafﬁnity depletion and various fractionation approaches
in combination with substantial improvements in LC–MS plat-
forms have enabled the plasma/tissue proteome to be proﬁled
with a considerably greater dynamic range of coverage, allowing
the identiﬁcation of several proteins at low ng/ml levels. Despite
these signiﬁcant advances, major challenges associated with the
dynamic range of measurements and extent of proteome cover-
age, conﬁdence of peptide/protein identiﬁcations, quantitation
accuracy, analysis throughput, and robustness of present instru-
mentation must be addressed before a proteomics proﬁling plat-
form suitable for efﬁcient clinical applications may be routinely
used in the accurate diagnosis of early liver damage, as well as
to monitor disease progression and assess treatment efﬁcacy
[129].
Based on previous investigations describing the main
targets of ROS and RNS-dependent protein oxidation/nitrosation,
redox proteomics approaches [130] were performed in vitro
experiments by treating liver tissue or hepatocytes with speciﬁc
oxidants, such hydrogen peroxide, diamide, menadione, t-butyl-
hydroperoxide and S-nitroso-L-cysteine [130–133]. These studies
identiﬁed early protein markers of thiol modiﬁcation, which are
subjected to glutathionylation, sulphenation or nitrosation
reactions. Although still preliminary and inconclusive, this
scenario emphasizes the potential role of proteomics and redox
proteomics technologies in the development of liver-speciﬁc
diagnostics and therapeutics. These holistic hold promise for
the identiﬁcation of biomarker proteins implicated in the devel-
opment of CLD and of protein targets of the ROS/RNS insult
during pathophysiological phenomena. It has to be mentioned,
however, that while various proteomic studies have described
the quantitative changes in the protein proﬁle of hepatic cells
or tissues during the pathological income, a very limited number
of investigations have described their redox-associated modi-
ﬁcations.Conclusions and perspectives
Treatment with antioxidants has been shown to be beneﬁcial
under controlled conditions in cell-free or in vitro cell systems,
but the expectation of this translational application to human
liver disease has not been yet fulﬁlled. Too often the evidence
for a general ROS formation is provided without the evaluation
of cellular sources, the nature of ROS and identiﬁcation of initiat-
ing events. This can lead to misinterpretation of the inner mech-
anisms and ultimately jeopardizes the translation of the ﬁndings
to the human pathophysiology. This may explain the reason why
despite the fact that ROS appear to be important in every exper-
imental model of inﬂammatory liver disease, no drug that target
ROS is currently available for human therapy. More detailed stud-
ies are warranted to elucidate: (i) the molecular mechanisms of
liver tissue injury and repair during an acute inﬂammatory
response and (ii) the role of ROS in these processes to translate
into better management of the use of antioxidant and ROS scav-
engers in the therapy of liver diseases. We hope and expect the
future will ﬁll the gap.Journal of Hepatology 201Key Points
• A correct balance between pro- and anti-oxidant events
(RedOx state) is crucial for a correct function of any
living cell. Oxidative events lead to the production
of Reactive Oxygen Species (ROS), and are rapidly
counteracted by several, different mechanisms
• Intracellular ROS may control the function of 
transcription factors, such as Nrf1 and NF-κB, leading
to profound changes in cellular gene expression profile
which are at the basis of several pathological conditions
in the liver
• Acute and chronic liver diseases are characterized by an
imbalance of the redox state toward an oxidative status.
This may be at the basis of common cellular events as
inflammation and cell damage
• HCV infection, NAFLD and NASH, cirrhosis and iron
accumulation are good examples of liver diseases
associated with an altered redox state, though clinical
data are still poorly defined
• Few, scattered data are available on molecular 
biomarkers of ROS production and redox alteration in
clinical settings. This prevented so far investigation of
the potential diagnostic and prognostic values of this
status
• A better understanding of the redox state in different liver
diseases will allow to better explore the potential efficacy
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